Autocrine TNF-α Increases Penetration of Myelin-Associated Glycoprotein Antibodies Across the Blood-Nerve Barrier in Anti-MAG Neuropathy
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 10, 2022
- Accepted in final form November 28, 2022
- First Published February 21, 2023.
Author Disclosures
- Ryota Sato, MD,
- Fumitaka Shimizu, MD, PhD,
- Motoi Kuwahara, MD, PhD,
- Yoichi Mizukami, MD, PhD,
- Kenji Watanabe, PhD,
- Toshihiko Maeda, MD, PhD,
- Yasuteru Sano, MD, PhD,
- Yukio Takeshita, MD, PhD,
- Michiaki Koga, MD, PhD,
- Susumu Kusunoki, MD, PhD and
- Takashi Kanda, MD, PhD
- Ryota Sato, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Fumitaka Shimizu, MD, PhD,
None
NONE
None
Frontiers in Neurology, section Multiple Sclerosis and Neuroimmunology, Associate Editor, 2022
NONE
NONE
Biogen, postdoctoral scientist, 1 years 10 month(2014.11-2016.8)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Motoi Kuwahara, MD, PhD,
None
NONE
(1)Takeda Pharmaceutical, speaker honoraria(2)Japan Blood Products Organization, speaker honoraria(3)CSL Behring, speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Yoichi Mizukami, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Kenji Watanabe, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Toshihiko Maeda, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Yasuteru Sano, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Yukio Takeshita, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Michiaki Koga, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Susumu Kusunoki, MD, PhD and
(1)ARGENX. Data safety monitoring board.
NONE
(1)Teijin Pharma, speaker honoraria, (2) Nihon Pharmaceuticals, speaker honoraria, (3) Japan Blood Products Organization, speaker honoraria, (4) CSL Behring, speaker honoraria, (5) Alexion, speaker honoraria, (6) Sinotest, speaker honoraria, and (7) Protosera, speaker honoraria.
(1) Journal of Neuroimmunology, editorial board member, 14 years, (2) Neurology and Clinical Neuroscience, editor in chief, 4 years, (3) JMA Journal, editorial board member, 5 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Ministry of Health, Labour and Welfare of Japan (Health and Labour Sciences Research Grant on Rare and Intractable Diseases (Validation of Evidence-based Diagnosis and Guidelines, and Impact on QOL in Patients with Neuroimmunological Diseases)
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Takashi Kanda, MD, PhD
(1) CSL Behring(2) Chugai Paharmaceutical Co.
NONE
(1) Novartis Pharma Co, speaker honoraria(2) Otsuka Pharmaceutical, speaker honoraria(3) Ayumi Pharmaceutical, speaker honoraria(4) Japan Blood, speaker honoraria(5) Takeda Pharmaceutical Co., speaker honoraria(6) Kyowa-Kirin Pharmaceutical Co., speaker honoraria(7) Sumitomo Pharmaceutical Co., speaker honoraria(8) Tanabe Mitsubishi Pharmaceutical Co., speaker honoraria(9) CSL Behring,, speaker honoraria(10) Janssen Pharmaceutical Co., speaker honoraria(11) Teijin Pharm., speaker honoraria(12) Biogen Japan, speaker honoraria(13) Eosai Pharmaceutical, speaker honoraria(14) Alexion Pharm., speaker honoraria(15) Glaxo Smith Klein, , speaker honoraria(16) Ono Pharmaceutical Co., speaker honoraria
(1) Clinical and Experimental Neuroimmunology Editor-in-Chief 2010-2018(2) Neuropathology, Editorial Advisory Board Member 2009-(3) Brain and Nerve Editor-in-Chief 2018-(4) Peripheral Nerve, Editor-in-Chief, 2017-2021(5) Fluids and Barriers of the CNS, Editor 2014-
(1) in vitro model of blood-brain barrier
NONE
NONE
(1) Teijin pharmaceutical Co.(1) CSL Behring
NONE
NONE
NONE
(1) Novartis Pharm.(2) Daiichi-Sankyo Co.(3) Asteras Co.
(1) Contract Grant Sponsor: Japan Society for the Promotion of Science - TokyoContract Grant Number: 25293203, 26670443, 17H04197
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology and Clinical Neuroscience (R.S., F.S., Y.S., Y.T., Michiaki Koga, T.K.), Yamaguchi University Graduate School of Medicine, Ube; Department of Neurology (Motoi Kuwahara, S.K.), Kindai University Faculty of Medicine, Osaka; Center for Gene Research (Y.M., K.W.), Yamaguchi University, Ube, Japan; and Japan Community Health Care Organization (S.K.).
- Correspondence
Dr. Shimizu fshimizu{at}yamaguchi-u.ac.jp
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.